Ann: Quarterly Activities & Cash Flow Report - Appendix 4C, page-16

Hey Windshift!

Thought I would add my two bob's worth here too - but I am not a holder of LBT.

LBT shares are likely to drift following the recent cap raise.

They need these trial sites to produce good comments from users and a demonstrable cost saving when the economics of switching systems to LPAS are lined up against existing systems.

One issue is the cost of sacking lab scientists that are made redundant.

The other problem is what to do when the LPAS breaks down or needs servicing.

No machine has 100% availability or 100% reliability.

So, if hospitals need a backup machine as well as the workhorse, the economics may not look quite so compelling.

I don't know the complete facts, but raise it as a possible issue for you to ponder.

They also need to start selling units.

It is a clear advance in lab automation but the health system is that screwed in Australia (due to incompetent and corrupt state governments who stave hospitals of funding) that getting a sale to a public hospital almost impossible.

So, it may well be great technology, it may save hospital money (even if they have to have a backup unit) but there is always inertia and there is the cost of eliminating staff.

Rush slowly into this one....

Cheers & GLTA